ArticleThe Journal of infectious diseases2019
Diverse Clinical Isolates of Mycobacterium tuberculosis Develop Macrophage-Induced Rifampin Tolerance.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A Dose-Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis.Clinical pharmacology and therapeutics · 2024Trial
- Drug-resistance profiles, population structure, genomic clustering, and temporal trends in drug resistance amongThe Lancet regional health. Europe · 2026Article
- MakingCell insight · 2026Review
- The Impact of Animal Models and Strain Standardization on the Evaluation of Tuberculosis Vaccine Efficacy.Vaccines · 2025Review
- The chosen few:Frontiers in immunology · 2024Review
- Gaucher disease protects against tuberculosis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The human proton pump inhibitors inhibitProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.PloS one · 2023Article
- Role of a Putative Alkylhydroperoxidase Rv2159c in the Oxidative Stress Response and Virulence ofPathogens (Basel, Switzerland) · 2022Article
- Unraveling the mechanisms of intrinsic drug resistance inFrontiers in cellular and infection microbiology · 2022Review
- The evolving biology ofFrontiers in cellular and infection microbiology · 2022Review
- The within-host evolution of antimicrobial resistance in Mycobacterium tuberculosis.FEMS microbiology reviews · 2021Review
- Identification of Novel Chemical Scaffolds that Inhibit the Growth ofFrontiers in pharmacology · 2021Article
- Genetic Diversity inAnnual review of genetics · 2020Review
- Short-Chain Fatty Acids PromotePathogens (Basel, Switzerland) · 2020Article
Corrections and comments
- Erratum issuedCorrigendum.2019
Authors and funding
11 authors.
Funding
Abstract
The Mycobacterium tuberculosis lineage 4 strains CDC1551 and H37Rv develop tolerance to multiple antibiotics upon macrophage residence. To determine whether macrophage-induced tolerance is a general feature of clinical M. tuberculosis isolates, we assessed macrophage-induced drug tolerance in strains from lineages 1-3, representing the other predominant M. tuberculosis strains responsible for tuberculosis globally. All 3 lineages developed isoniazid tolerance. While lineage 1, 3, and 4 strains developed rifampin tolerance, lineage 2 Beijing strains did not. Their failure to develop tolerance may be explained by their harboring of a loss-of-function mutation in the Rv1258c efflux pump that is linked to macrophage-induced rifampicin tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.